#NEWS: Today Endeavor BioMedicines announced new results from a Phase 2a clinical trial of our lead investigational candidate, ENV-101, in patients with idiopathic pulmonary fibrosis (IPF). The results were presented for the first time today during a late-breaking oral session at the American Thoracic Society International Conference (#ATS2024). Read more here: https://bit.ly/3V4Lkm1 #pulmonaryfibrosis #biotechnews #clinicaltrials
wishing you guys all the best!
This is awesome! Congrats Endeavor BioMedicines team!
Congrats Endeavor BioMedicines!
Pharma Informatics Specialist | KOL Insights Specialist | Thought Leader Engagement 💡 | Supporting Medical Action Plans and RWE generations with AI Tools 🤖
3moCongratulations team Endeavor BioMedicines! 🥂 on Phase 2a trial results for ENV-101. Keen to know how you deal with KOL engagements.